Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.
Want to test your EoE knowledge while learning more about the patient journey? Try EoE Quest, an engaging and educational interactive experience.

Learn about key drivers of type 2 inflammation in EoE and how they mediate progressive esophageal remodeling and impact patient burden

Learn about the importance of assessing key disease domains in EoE by focusing on symptoms, QoL, endoscopy, and histology.
Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation

The infographic provides information about the clinical characteristics used to classify moderate COPD exacerbations and the impact of these events on lung function, future risk, and mortality.
Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.